Lineup Debut! Haisco Pharmaceutical, Yueton Pharmaceuticals, Jiuyuan Gene, Daor Bio... Submit IPO Prospectuses
GSK
Pharmaceutical R&D Manufacturer
The peptide frenzy ignited by GLP-1 continues, but the industry’s focus has quietly shifted: cyclic peptides, PDCs, multi-target agonists, and AI-assisted design—who will emerge as the next breakthrough?
[CBI2026 Peptide Drug Innovation, Development, and Manufacturing Conference]To be held at Hall B, Room 107 of the Suzhou International Expo Center. Co-hosted by Apeloa Pharmaceutical and YaoRongQuan, this conference focuses on core topics including differentiated development of peptide drugs, clinical progress, and CMC manufacturing. It brings together leading domestic pharmaceutical companies and emerging biotech industry experts for in-depth exchanges, addressing pain points across the entire chain from early-stage R&D to commercial production. Free registration is welcome!
Forum Name:CBI2026Frontier Forum on Peptide Drugs and GLP-1
Forum Schedule:September 4-5, 2026
Forum Venue:Hall B, Booth B103, Suzhou International Expo Center
Co-hosted by:Apeloa Pharmaceutical, PharmCube
*Sorted alphabetically by first letter of name (A–Z); no special significance intended
Holds a B.S. in Biochemistry from Wuhan University and an M.S. in Bioengineering from Shanghai Jiao Tong University; Senior Engineer; qualified as a Fund Practitioner and Technology Transfer Professional; serves as an expert reviewer for projects under the Shenzhen Municipal Commission of Economy and Trade and the Shenzhen Municipal Science and Technology Innovation Commission; currently Deputy General Manager of the Guangdong Provincial Small Molecule New Drug Innovation Center & Shenzhen Xinyue Biotechnology; Founder of the “Pharma Talk Club”; Vice President of the Shenzhen Life Sciences and Biotechnology Association; possesses 22 years of experience in pharmaceutical production, quality assurance, R&D, business development, and industrial investment, having previously worked at Xinpeng Biotechnology, Neptunus Biotech, Ausa Pharmaceuticals, Zhongzheng Pharmaceutical, and Peking University Weiming Group.
In the field of pharmaceutical R&D, possesses 10 years of experience in Marketing Authorization Holder (MAH) R&D (covering 12 MAH chemical R&D projects, with 9 clinical trial approvals and 1 biologic production approval obtained) and 8 years of independent R&D experience (securing 2 biologic clinical projects and 1 production approval). In terms of industrial investment, has successfully merged with or acquired multiple pharmaceutical enterprises (including the GSK Shenzhen manufacturing plant). In recent years, focus has been placed on the investment, incubation, and technological transfer of early-stage innovative biomedical projects, among which one Class I new drug received clinical trial approval from both the Chinese NMPA and the US FDA in July 2023. Successfully introduced and industrialized one specialized medical food product from France, and completed several technology transfer projects (covering Class I, Class III, and Class VI new drug projects).
Dr. Haifeng Cui earned his Ph.D. in Organic Chemistry from the University of Pennsylvania. He subsequently joined GSK US, where he worked for 17 years across multiple therapeutic areas, serving as Scientific Director and GSK Fellow. He led more than 10 first-in-class (FIC) projects, covering the entire process from novel target identification to clinical proof-of-concept (PoC), and was a key contributor to the development of gepotidacin, a novel-mechanism oral broad-spectrum antibiotic approved by the FDA in 2025. In 2019, he joined the Janssen Innovation Center as Senior Director, responsible for identifying and evaluating partnership opportunities in infectious diseases, immunology, metabolism, and neuroscience in the Asia-Pacific region. In 2021, he joined Shanghai Jiyu as Chief Scientific Officer (CSO) and Head of R&D, advancing over 20 projects into clinical trials within five years, achieving one new drug approval and four overseas licensing deals. In early 2026, he joined Hailiang Pharma as CSO.
Dr. Yongliang Fang received his bachelor’s degree from China Pharmaceutical University and subsequently earned his Ph.D. from Dartmouth College in the United States. His primary research interests include protein engineering, immunogenicity analysis, protein engineering to reduce immunogenicity, drug discovery, and clinical translation. As a co-founder and Chief Operating Officer of Occulo Inc. in the U.S., he spearheaded the company’s Series A financing, pipeline development, licensing of key assets, and outbound project licensing. Currently, he serves as the Chief Operating Officer of Zhejiang Daoer Biotechnology Co., Ltd., where he is primarily responsible for innovative drug registration, clinical translation and operations, and business development.
Song Gengshen, Ph.D., Senior Engineer (Professor Level), Dean of the Drug Research Institute at Yuekang Pharmaceutical Group Co., Ltd., and Director of the National-Local Joint Engineering Center for Nucleic Acid Drugs. He concurrently serves as Vice Chairman and Secretary-General of the Biomarker Professional Committee of the Chinese Research Hospital Association, Vice Chairman of the Pharmaceutical Excipients Professional Committee of the Chinese Pharmaceutical Association, Member of the Drug R&D Professional Committee of the China Association for Pharmaceutical Innovation, and Member of the Nucleic Acid Vaccine Branch of the China Vaccines Industry Association. His work focuses on the research and development of mRNA therapies, small nucleic acid drugs, and LNP delivery systems. He oversees multiple R&D pipelines for mRNA vaccines, small nucleic acid drugs, and peptide drugs.
Graduated from Peking University and Zhejiang University, currently serving as the Technical Director of Hangzhou Jiuyuan Gene Biopharmaceutical Co., Ltd. With over twenty years of experience in the research, development, and industrialization of peptide and protein drugs, he has facilitated the approval of production licenses or clinical trial permissions for multiple peptide, recombinant protein, and monoclonal antibody drugs. Notably, he led the team that developed the first domestically approved liraglutide biosimilar and submitted the first domestic application for marketing approval of a semaglutide biosimilar. He has presided over or participated in more than ten major projects, including the National Major New Drug Creation Program and key projects in Zhejiang Province. He has received awards such as the Zhejiang Provincial Science and Technology Award and has been selected for talent programs including Zhejiang Provincial Leading Talent and Hangzhou’s “West Lake Pearl” initiative.
Topic 1: Source Discovery and Early Research of GLP-1 and Peptide Drugs
Differentiated Development of Peptide Drugs in the Field of Chronic Metabolic Diseases
Peptide Drug Development in the Weight Loss Field
Breakthroughs in Technical Barriers to Cyclic Peptide Drug Development
The "Green Path" for the Development of Natural Peptide Drugs
Differentiated Peptide-Drug Conjugate Development
Multifunctional Specific Peptide Drug Development Strategy
AI-Driven Innovative Development of Peptide Drugs
GLP-1 Combination Therapy: GLP-1/GIP/Glucagon Triple-Target Agonist
Research Progress on Long-Acting GLP-1 Receptor Agonists
Topic 2: Innovation and Iteration of Peptide and GLP-1 Drugs, and Advances in Clinical Development
The Expansion of “Super Indications” for GLP-1 Drugs
The Battle for the High Ground in the GLP-1 Sector
Opportunities for Chinese Peptide Drugs to Go Global
Clinical Development Strategy and Value Reshaping of GLP-1 Drugs
Differentiated Clinical Development of Long-Acting Multi-Target GLP-1 Agonists
Clinical Development Challenges and Advances in Oral GLP-1 Drugs
Development and Registration Strategy for Phase III Clinical Programs of Peptide Drugs
Topic 3: Process Development of Peptide Drugs
Key Points on CMC of Peptide-Drug Conjugates
Research Progress on Long-Acting Formulations of Peptide Drugs
Process and Quality Research on Novel Peptide Drugs
Exploration of Optimization and Improvement of Peptide Preparations
Quality Control and Analytical Methods for Peptide Active Pharmaceutical Ingredients
Regulatory Requirements for Peptide CMC
Peptide Process Development and Laboratory
Impurity Studies of Peptide Drug Formulations
GMP Specifications for Peptide Drug Production
Registration:
ConferenceLimited-Time Free Access(Limited spots available; registration is on a first-come, first-served basis. This is a pre-registration, and successful registration is confirmed upon approval of the application.) Accommodation and meals are at the participant’s own expense.
